Adagene Inc (ADAG)vsRevolution Medicines Inc (RVMD)
ADAG
Adagene Inc
$3.72
-0.27%
HEALTHCARE · Cap: $243.15M
RVMD
Revolution Medicines Inc
$192.17
+6.22%
HEALTHCARE · Cap: $39.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Adagene Inc generates 934% more annual revenue ($7.67M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -229.6%. RVMD earns a higher WallStSmart Score of 24/100 (F).
ADAG
Avoid21
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 7333.0% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -144.5% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADAG
The strongest argument for ADAG centers on Revenue Growth, Debt/Equity. Revenue growth of 7333.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ADAG
The primary concerns for ADAG are EPS Growth, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ADAG profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
ADAG is growing revenue faster at 7333.0% — sustainability is the question.
ADAG generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
RVMD scores higher overall (24/100 vs 21/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?